Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
暂无分享,去创建一个
[1] S. Love,et al. Elevated Activity and Microglial Expression of Myeloperoxidase in Demyelinated Cerebral Cortex in Multiple Sclerosis , 2008, Brain pathology.
[2] David H. Miller,et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. , 2002, Brain : a journal of neurology.
[3] R. Reynolds,et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. , 2012, Brain : a journal of neurology.
[4] P. Hanson,et al. Edinburgh Research Explorer Mitochondrial Changes within Axons in Multiple Sclerosis Mitochondrial Changes within Axons in Multiple Sclerosis , 2022 .
[5] H. Bading,et al. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders , 2010, Nature Reviews Neuroscience.
[6] Richard Reynolds,et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis , 2011, Annals of neurology.
[7] D. Centonze,et al. Inflammation Triggers Synaptic Alteration and Degeneration in Experimental Autoimmune Encephalomyelitis , 2009, The Journal of Neuroscience.
[8] A. Thompson,et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. , 2003, Brain : a journal of neurology.
[9] P. Elliott,et al. Oral Resveratrol Reduces Neuronal Damage in a Model of Multiple Sclerosis , 2010, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.
[10] W Craelius,et al. Iron deposits surrounding multiple sclerosis plaques. , 1982, Archives of pathology & laboratory medicine.
[11] H. Weiner. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis , 2008, Journal of Neurology.
[12] Alessandro Martorana,et al. Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis , 2009, Neurobiology of Disease.
[13] M. Ramanathan,et al. Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. , 2007, Human molecular genetics.
[14] D. Pitt,et al. Glutamate excitotoxicity in a model of multiple sclerosis , 2000, Nature Medicine.
[15] Pierre J. Magistretti,et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration , 2012, Nature.
[16] A. Echaniz-Laguna,et al. POLG1 variations presenting as multiple sclerosis. , 2010, Archives of neurology.
[17] F. Abboud,et al. Extracellular acidosis increases neuronal cell calcium by activating acid-sensing ion channel 1a. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[18] P. Gustafson,et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. , 2012, JAMA.
[19] Pardis C Sabeti,et al. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene , 2009, Molecular Psychiatry.
[20] Gwo-hsiao Chen,et al. Loss of Na+ channel β2 subunits is neuroprotective in a mouse model of multiple sclerosis , 2009, Molecular and Cellular Neuroscience.
[21] B. Scheithauer,et al. Inflammatory cortical demyelination in early multiple sclerosis. , 2011, The New England journal of medicine.
[22] R. Rudick,et al. Neurological disability correlates with spinal cord axonal loss and reduced N‐acetyl aspartate in chronic multiple sclerosis patients , 2000, Annals of neurology.
[23] D. Turnbull,et al. Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis. , 2011, Brain : a journal of neurology.
[24] S. Zamvil,et al. K+ channel alterations in the progression of experimental autoimmune encephalomyelitis , 2012, Neurobiology of Disease.
[25] David H. Miller,et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial , 2009, The Lancet Neurology.
[26] D. Centonze,et al. Cannabinoid CB1 receptors regulate neuronal TNF-α effects in experimental autoimmune encephalomyelitis , 2011, Brain, Behavior, and Immunity.
[27] X. Montalban,et al. The value of animal models for drug development in multiple sclerosis. , 2006, Brain : a journal of neurology.
[28] S. Waxman,et al. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine , 2007, Annals of neurology.
[29] R. Reynolds,et al. Molecular Changes in Normal Appearing White Matter in Multiple Sclerosis are Characteristic of Neuroprotective Mechanisms Against Hypoxic Insult , 2003, Brain pathology.
[30] Hans Lassmann,et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains , 2009, Brain : a journal of neurology.
[31] Hans Lassmann,et al. Widespread Demyelination in the Cerebellar Cortex in Multiple Sclerosis , 2007, Brain pathology.
[32] Shyam Biswal,et al. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. , 2007, Annual review of pharmacology and toxicology.
[33] A. Salinaro,et al. Redox regulation of cellular stress response in multiple sclerosis. , 2011, Biochemical pharmacology.
[34] H. Lassmann,et al. Explorer NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury , 2012 .
[35] G. Ketels,et al. Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial , 2014, Multiple sclerosis.
[36] Hans Lassmann,et al. Activated Human T Cells, B Cells, and Monocytes Produce Brain-derived Neurotrophic Factor In Vitro and in Inflammatory Brain Lesions: A Neuroprotective Role of Inflammation? , 1999, The Journal of experimental medicine.
[37] A. Minagar,et al. Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis , 2011 .
[38] R. Sergott. Imaging correlates of decreased axonal Na+/K+ ATPase in chronic multiple sclerosis lesions , 2008 .
[39] A J Thompson,et al. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.
[40] Xavier Golay,et al. Sodium accumulation is associated with disability and a progressive course in multiple sclerosis. , 2013, Brain : a journal of neurology.
[41] E. Sribnick,et al. Upregulation of calpain correlates with increased neurodegeneration in acute experimental auto‐immune encephalomyelitis , 2005, Journal of neuroscience research.
[42] E. Melamed,et al. Mice overexpressing Bcl-2 in their neurons are resistant to myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) , 2000, Journal of Molecular Neuroscience.
[43] T. Olsson,et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab , 2011, Annals of neurology.
[44] Mary T. Brinkoetter,et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis , 2011, Nature Medicine.
[45] R. Reynolds,et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. , 2011, Brain : a journal of neurology.
[46] R. Gold,et al. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration , 2006, Clinical and experimental immunology.
[47] Jörg R. P. Geiger,et al. Energy-Efficient Action Potentials in Hippocampal Mossy Fibers , 2009, Science.
[48] Bruce P. Bean,et al. Sodium Entry during Action Potentials of Mammalian Neurons: Incomplete Inactivation and Reduced Metabolic Efficiency in Fast-Spiking Neurons , 2009, Neuron.
[49] D. Bourdette,et al. Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis , 2007, Proceedings of the National Academy of Sciences.
[50] S. Confort-Gouny,et al. Block of neural Kv1.1 potassium channels for neuroinflammatory disease therapy , 2006, Annals of neurology.
[51] K. Selmaj,et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. , 2010, Brain : a journal of neurology.
[52] H. Lassmann,et al. Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. , 2001, Brain : a journal of neurology.
[53] G. Comi,et al. MGAT5 alters the severity of multiple sclerosis , 2010, Journal of Neuroimmunology.
[54] S. Elkabes,et al. Beneficial effect of erythropoietin on experimental allergic encephalomyelitis , 2004, Annals of neurology.
[55] K. Jellinger,et al. Preferential Loss of Myelin‐Associated Glycoprotein Reflects Hypoxia‐Like White Matter Damage in Stroke and Inflammatory Brain Diseases , 2003, Journal of neuropathology and experimental neurology.
[56] H. D. de Vries,et al. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. , 2008, Free radical biology & medicine.
[57] D. Sparks,et al. Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity , 2008, Glia.
[58] O. Pongs,et al. TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis , 2012, Nature Medicine.
[59] A. Redensek,et al. Ceruloplasmin Protects Injured Spinal Cord from Iron-Mediated Oxidative Damage , 2008, The Journal of Neuroscience.
[60] Simon Hametner,et al. Disease-specific molecular events in cortical multiple sclerosis lesions , 2013, Brain : a journal of neurology.
[61] H. Lassmann,et al. CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation , 2002, Nature Medicine.
[62] G. Krissansen,et al. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. , 2004, Brain : a journal of neurology.
[63] Peter K Stys,et al. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis , 2009, The Lancet Neurology.
[64] E. Brand-Schieber,et al. Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis , 2004, Experimental Neurology.
[65] M. Daumer,et al. Early relapses, onset of progression, and late outcome in multiple sclerosis. , 2013, JAMA neurology.
[66] C. Lucchinetti,et al. Pathology of demyelinating diseases. , 2012, Annual review of pathology.
[67] Martin Röcken,et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells , 2012 .
[68] A. Blight,et al. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis , 2011, Current medical research and opinion.
[69] DelindaA . Johnson,et al. The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[70] C. Ledent,et al. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis , 2008, Journal of Neuroimmunology.
[71] T. Bíró,et al. Transient receptor potential channels as therapeutic targets , 2011, Nature Reviews Drug Discovery.
[72] L. Turski,et al. Autoimmune encephalomyelitis ameliorated by AMPA antagonists , 2000, Nature Medicine.
[73] L. Fugger,et al. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system , 2007, Nature Medicine.
[74] W. Brück,et al. Molecular Changes in White Matter Adjacent to an Active Demyelinating Lesion in Early Multiple Sclerosis , 2009, Brain pathology.
[75] P. Stys,et al. Mechanisms of axonal injury: internodal nanocomplexes and calcium deregulation. , 2010, Trends in molecular medicine.
[76] R. Rudick,et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients , 2006, Annals of neurology.
[77] J. Kemp,et al. NMDA receptor pathways as drug targets , 2002, Nature Neuroscience.
[78] H. Weiner,et al. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. , 2008, The Journal of clinical investigation.
[79] D. Bechtold,et al. Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. , 2013, Brain : a journal of neurology.
[80] H. Broxmeyer. Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration , 2013, The Journal of experimental medicine.
[81] D. Bechtold,et al. Axonal protection achieved in a model of multiple sclerosis using lamotrigine , 2006, Journal of Neurology.
[82] D. Bechtold,et al. Axonal protection using flecainide in experimental autoimmune encephalomyelitis , 2004, Annals of neurology.
[83] George C. Ebers,et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability , 2010, Brain : a journal of neurology.
[84] J. Dunn,et al. Susceptibility-weighted imaging in the experimental autoimmune encephalomyelitis model of multiple sclerosis indicates elevated deoxyhemoglobin, iron deposition and demyelination , 2013, Multiple sclerosis.
[85] J. Newcombe,et al. Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration , 2012, The Journal of experimental medicine.
[86] John A. Wemmie,et al. Acid-sensing ion channels in pain and disease , 2013, Nature Reviews Neuroscience.
[87] Jia Newcombe,et al. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[88] Christine Stadelmann,et al. Wallerian Degeneration: A Major Component of Early Axonal Pathology in Multiple Sclerosis , 2010, Brain pathology.
[89] J. M. Ritchie,et al. Molecular dissection of the myelinated axon , 1993, Annals of neurology.
[90] M. Jenkinson,et al. Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride. , 2013, Brain : a journal of neurology.
[91] W. Brück,et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. , 2000, Brain : a journal of neurology.
[92] A. Verma,et al. Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study , 2008 .
[93] D. Attwell,et al. Updated Energy Budgets for Neural Computation in the Neocortex and Cerebellum , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[94] Michael R. Johnson,et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. , 2009, Human molecular genetics.
[95] P. D. Jager,et al. Genome-wide association study of severity in multiple sclerosis , 2011, Genes and Immunity.
[96] Martin Daumer,et al. Onset of secondary progressive phase and long-term evolution of multiple sclerosis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[97] A. Hodgkin. The optimum density of sodium channels in an unmyelinated nerve. , 1975, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[98] Hellmut Merkle,et al. Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. , 2011, Brain : a journal of neurology.
[99] D. Wallace,et al. Mitochondrial energetics and therapeutics. , 2010, Annual review of pathology.
[100] Jeremy Hobart,et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial , 2013, The Lancet Neurology.
[101] D. Centonze,et al. Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis , 2013, British journal of pharmacology.
[102] V. Gallai†,et al. Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. , 2003, Archives of neurology.
[103] W. Brück,et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. , 2011, Brain : a journal of neurology.
[104] R. Gold,et al. Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination , 2011, Acta Neuropathologica.
[105] Christian Langkammer,et al. Iron and Neurodegeneration in Multiple Sclerosis , 2011, Multiple sclerosis international.
[106] Simon Hametner,et al. Iron and neurodegeneration in the multiple sclerosis brain , 2013, Annals of neurology.
[107] Frederik Barkhof,et al. Grey matter pathology in multiple sclerosis , 2008, The Lancet Neurology.
[108] Axel Petzold,et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis , 2010, The Lancet Neurology.
[109] H. Wiendl,et al. The TASK1 channel inhibitor A293 shows efficacy in a mouse model of multiple sclerosis , 2012, Experimental Neurology.
[110] C. Bolton,et al. Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine. , 2002, The Journal of pharmacology and experimental therapeutics.
[111] Pradeep J. Nathan,et al. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases , 2013, Nature Reviews Neuroscience.
[112] H. Lassmann,et al. Oxidative damage in multiple sclerosis lesions , 2011, Brain : a journal of neurology.
[113] M. Tuszynski,et al. Potential therapeutic uses of BDNF in neurological and psychiatric disorders , 2011, Nature Reviews Drug Discovery.
[114] Pico Caroni,et al. Selective Neuronal Vulnerability in Neurodegenerative Diseases: from Stressor Thresholds to Degeneration , 2011, Neuron.
[115] C. Ledent,et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells , 2007, Nature Medicine.
[116] A. Lo,et al. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS , 2005, Glia.
[117] G. Comi,et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. , 2012, The American journal of pathology.
[118] Keith Baar,et al. Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases , 2012, Cell.
[119] Kenneth J. Smith,et al. Electrically active axons degenerate when exposed to nitric oxide , 2001, Annals of neurology.
[120] J. Newcombe,et al. Glutamate Receptor Expression in Multiple Sclerosis Lesions , 2008, Brain pathology.
[121] Y. Zhang,et al. Distinct role of nitric oxide and peroxynitrite in mediating oligodendrocyte toxicity in culture and in experimental autoimmune encephalomyelitis , 2011, Neuroscience.
[122] L. Fugger,et al. Therapies for multiple sclerosis: translational achievements and outstanding needs. , 2013, Trends in molecular medicine.
[123] R. Mutani,et al. Altered Glutamate Reuptake in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis Cortex: Correlation With Microglia Infiltration, Demyelination, and Neuronal and Synaptic Damage , 2007, Journal of neuropathology and experimental neurology.
[124] M. Eder,et al. CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity , 2003, Science.
[125] M. Cuénod,et al. Murine brain macrophages induce NMDA receptor mediated neurotoxicity in vitro by secreting glutamate , 1991, Neuroscience Letters.
[126] B. Trapp,et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.
[127] P. Fontoura,et al. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. , 2007, The Journal of clinical investigation.
[128] Arthur F. Kramer,et al. Aerobic fitness is associated with gray matter volume and white matter integrity in multiple sclerosis , 2010, Brain Research.
[129] M. Ramanathan,et al. Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: A voxel-based morphometry study. , 2011, Pathophysiology : the official journal of the International Society for Pathophysiology.
[130] A. Lo,et al. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. , 2003, Journal of neurophysiology.
[131] Alistair Mathie,et al. Therapeutic potential of neuronal two-pore domain potassium-channel modulators. , 2007, Current opinion in investigational drugs.
[132] M. Esiri,et al. Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. , 2011, Brain : a journal of neurology.
[133] P. Launay,et al. Physiological roles of the TRPM4 channel extracted from background currents. , 2010, Physiology.
[134] B. Seitz,et al. A randomized, double‐blind, phase 2 study of erythropoietin in optic neuritis , 2012, Annals of neurology.
[135] L. Kappos,et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis , 2011, Neurology.
[136] David H. Miller,et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial , 2010, The Lancet Neurology.
[137] David H. Miller,et al. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials , 2009, Nature Reviews Neurology.
[138] Hans Lassmann,et al. Progressive multiple sclerosis: pathology and pathogenesis , 2012, Nature Reviews Neurology.
[139] M. Esiri,et al. The contribution of demyelination to axonal loss in multiple sclerosis. , 2006, Brain : a journal of neurology.
[140] Axel Petzold. Optical Coherence Tomography in Multiple Sclerosis , 2016 .
[141] S. Khoury,et al. Protecting Axonal Degeneration by Increasing Nicotinamide Adenine Dinucleotide Levels in Experimental Autoimmune Encephalomyelitis Models , 2006, The Journal of Neuroscience.
[142] F. Mokhtarian,et al. Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis , 2008, Brain Research.
[143] R. Bronson,et al. Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration. , 2007, The American journal of pathology.
[144] Frauke Zipp,et al. Neuronal Damage in Autoimmune Neuroinflammation Mediated by the Death Ligand TRAIL , 2005, Neuron.
[145] H. Lassmann,et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. , 2000, The American journal of pathology.
[146] D. Bayliss,et al. TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. , 2009, Brain : a journal of neurology.
[147] Richard Reynolds,et al. HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage , 2009, Nature Neuroscience.
[148] A. Compston,et al. Multiple sclerosis. , 2002, Lancet.
[149] E. Hogan,et al. Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[150] Hans Lassmann,et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. , 2005, Brain : a journal of neurology.
[151] Gregory C Kujoth,et al. Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice , 2011, Proceedings of the National Academy of Sciences.
[152] Jens Frahm,et al. Role of n‐type voltage‐dependent calcium channels in autoimmune optic neuritis , 2009, Annals of neurology.
[153] Howard T. Jacobs,et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase , 2004, Nature.
[154] T. Owens,et al. Glutamate metabolism is down‐regulated in astrocytes during experimental allergic encephalomyelitis , 1997, Glia.
[155] Hristian,et al. RELAPSES AND PROGRESSION OF DISABILITY IN MULTIPLE SCLEROSIS , 2000 .
[156] M. Beal,et al. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases , 2006, Nature.
[157] Masahiko Watanabe,et al. Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis , 2002, Journal of Neuroimmunology.
[158] W. Brück,et al. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? , 2002, Brain : a journal of neurology.
[159] Arunesh Mittal,et al. Casting light on multiple sclerosis heterogeneity: the role of HLA-DRB1 on spinal cord pathology. , 2013, Brain : a journal of neurology.
[160] M. Esiri,et al. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. , 2004, Brain : a journal of neurology.
[161] T. Olsson,et al. Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis , 1996, Journal of the Neurological Sciences.
[162] Stephen G Waxman,et al. Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. , 2004, Brain : a journal of neurology.
[163] Jens Frahm,et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity , 2012, Nature.
[164] M. Mattson,et al. Recruiting adaptive cellular stress responses for successful brain ageing , 2012, Nature Reviews Neuroscience.
[165] Hans Lassmann,et al. Mitochondrial defects in acute multiple sclerosis lesions , 2008, Brain : a journal of neurology.
[166] H. Neumann,et al. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. , 2010, Brain : a journal of neurology.